Research programme: bispecific antibodies - Immune PharmaceuticalsAlternative Names: Tetravalent bsAb - Immune Pharmaceuticals; Tetravalent IgG1-like bispecific antibody - Immune Pharmaceuticals
Latest Information Update: 06 Apr 2016
At a glance
- Originator Immune Pharmaceuticals Inc
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action B-cell maturation antigen modulators; CD274 antigen modulators; OX40 receptor modulators; PDCD 1 protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer